New anabolic therapies in XXXX .

@entity1555 @entity170 @entity461 @entity460
Anabolic agents represent an important new advance in the therapy of @entity170 . Their potential might be substantially greater than the anti-resorptives. Because the anti-resorptives and anabolic agents work by completely distinct mechanisms of action, it is possible that the combination of agents could be significantly more potent than either agent alone. Recent evidence suggests that a plateau in @entity1555 might occur after prolonged exposure to @entity461 . Anti-resorptive therapy during or after anabolic therapy might prevent this skeletal adaptation. Protocols to consider anabolic agents as intermittent recycling therapy would be of interest. Of all the anabolics, @entity461 is the most promising. However, there are unanswered questions about @entity461 . More studies are needed to document an anabolic effect on cortical bone. More large-scale studies are needed to further determine the reduction in nonvertebral fractures with @entity461 , especially at the hip. In the future, @entity461 is likely to be modified for easier and more targeted delivery. Oral or transdermal delivery systems may become available. Recently, Gowen et al have described an oral calcilytic molecule that antagonizes the parathyroid cell @entity460 receptor, thus stimulating the endogenous release of @entity461 . This approach could represent a novel endogenous delivery system for intermittent @entity461 administration. Rising expectations that anabolic therapies for @entity170 will soon play a major role in treating this disease are likely to fuel further studies and the development of even more novel approaches to therapy.
